Wendy A Gattis

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Overview of current noninodilator therapies for acute heart failure syndromes
    Wendy Gattis Stough
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 96:41G-6G. 2005
  2. ncbi request reprint Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure
    Wendy A Gattis
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Am J Cardiol 93:74B-6B. 2004
  3. ncbi request reprint Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial)
    Wendy A Gattis
    Duke Clinical Research Institute, Duke University Medical Center, 2400 N Pratt Street, Box 17969, Durham, NC 27710, USA
    Am J Cardiol 93:1436-7, A10. 2004
  4. ncbi request reprint Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure
    Wendy A Gattis
    Duke University Medical Center Duke Clinical Research Institute, Division of Cardiology, Durham, North Carolina 27705, USA
    Am J Cardiol 91:169-74. 2003
  5. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 41:1452-7. 2003
  6. ncbi request reprint Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 291:1963-71. 2004
  7. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, University of North Carolina, Chapel Hill, NC 27705, USA
    Am Heart J 144:583-8. 2002
  8. ncbi request reprint Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial
    Wendy A Gattis
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 43:1534-41. 2004
  9. ncbi request reprint Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 92:625-8. 2003
  10. ncbi request reprint The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications
    Wendy A Gattis
    Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Rev Cardiovasc Med 3:S48-54. 2002

Detail Information

Publications31

  1. ncbi request reprint Overview of current noninodilator therapies for acute heart failure syndromes
    Wendy Gattis Stough
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 96:41G-6G. 2005
    ....
  2. ncbi request reprint Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure
    Wendy A Gattis
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Am J Cardiol 93:74B-6B. 2004
    ..2% vs 73.4%, respectively). Based on the study's results, predischarge initiation may be a successful strategy to improve the use of beta-blocker therapy for patients with heart failure...
  3. ncbi request reprint Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial)
    Wendy A Gattis
    Duke Clinical Research Institute, Duke University Medical Center, 2400 N Pratt Street, Box 17969, Durham, NC 27710, USA
    Am J Cardiol 93:1436-7, A10. 2004
    ..One hundred ninety-two patients were enrolled in this study. Patients with baseline cTnI values were included in this analysis, and the relation between cTnI and the composite clinical primary end point of RITZ-4 was evaluated...
  4. ncbi request reprint Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure
    Wendy A Gattis
    Duke University Medical Center Duke Clinical Research Institute, Division of Cardiology, Durham, North Carolina 27705, USA
    Am J Cardiol 91:169-74. 2003
    ..These results also suggest that caution should be taken when withdrawing beta blockade in this population...
  5. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 41:1452-7. 2003
    ..We sought to determine the effect of tezosentan in patients with acute decompensated heart failure (HF) associated with acute coronary syndrome (ACS)...
  6. ncbi request reprint Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 291:1963-71. 2004
    ..In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function...
  7. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, University of North Carolina, Chapel Hill, NC 27705, USA
    Am Heart J 144:583-8. 2002
    ..Tezosentan is a dual endothelin receptor antagonist, and it has improved cardiac output and reduced pulmonary and systemic vascular resistance in experimental animal models and in initial human acute decompensated heart failure studies...
  8. ncbi request reprint Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial
    Wendy A Gattis
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 43:1534-41. 2004
    ....
  9. ncbi request reprint Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 92:625-8. 2003
    ..Lower baseline hemoglobin is associated with risk of short-term adverse clinical outcomes in this population, even after controlling for other baseline differences...
  10. ncbi request reprint The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications
    Wendy A Gattis
    Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Rev Cardiovasc Med 3:S48-54. 2002
    ..The trial data will determine if in-hospital initiation of beta-blocker therapy is effective at improving the long-term use of pharmacologic agents proven to reduce morbidity and mortality...
  11. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 145:S58-9. 2003
  12. ncbi request reprint Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S55-7. 2003
  13. ncbi request reprint Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis
    Michael P Hudson
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 147:546-52. 2004
    ..We assessed whether elevated TnT levels are associated with the severity, etiology, and prognosis of HF in stable, ambulatory patients...
  14. ncbi request reprint Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure
    Karen E Joynt
    Department of Medicine Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:783-5. 2004
    ..Baseline angiotensin-converting enzyme inhibitor plus beta-blocker use were associated with lower levels of CRP; no relation was found between CRP levels and aspirin or statin use...
  15. ncbi request reprint Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S51-4. 2003
  16. ncbi request reprint Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study
    Liviu Klein
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 93:44A-46A. 2004
    ....
  17. ncbi request reprint Anemia as a risk factor and therapeutic target in heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 44:959-66. 2004
    ..Multiple ongoing studies will provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF...
  18. ncbi request reprint Racial differences in the outcomes of patients with diastolic heart failure
    Mark A East
    Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 148:151-6. 2004
    ..This is particularly common in African American patients, yet there have been few studies examining the long-term natural history of this disorder in African-American and white patients...
  19. ncbi request reprint Treatment gaps in the pharmacologic management of heart failure
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Chicago, Illinois, USA
    Rev Cardiovasc Med 3:S11-9. 2002
    ..Other tools may also be considered, and testing the influence of such tools on the implementation of optimal therapy may help the scientific community better understand the factors that influence decision-making among clinicians...
  20. ncbi request reprint Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 145:S47-50. 2003
  21. ncbi request reprint OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Medical School, 201 E Huron Street, Galter 10 240, Chicago, IL 60611, USA
    Eur J Heart Fail 5:9-12. 2003
  22. ncbi request reprint Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design
    Gregg C Fonarow
    Department of Medicine, UCLA Medical Center, Los Angeles, Calif, USA
    Am Heart J 148:43-51. 2004
    ..The ultimate aim of this program is to improve the standard of HF care in the hospital and outpatient settings and increase the use of evidence-based therapeutic strategies to save lives...
  23. ncbi request reprint Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis
    Kirkwood F Adams
    Department of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27517, USA
    J Am Coll Cardiol 46:497-504. 2005
    ..The purpose of this study was to investigate the relationship of serum digoxin concentration (SDC) and outcomes in women with heart failure (HF)...
  24. ncbi request reprint Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations
    Liviu Klein
    Advocate Illinois Masonic Medical Center, Chicago, Illinois 60607, USA
    Am J Cardiol 91:18F-40F. 2003
    ..Finally, anticoagulation is recommended only in patients who have concomitant atrial fibrillation or a previous history of cerebral or systemic emboli...
  25. ncbi request reprint Surrogate end points in heart failure trials
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S67-70. 2003
  26. ncbi request reprint Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial
    Manuela Zampino
    Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S62-6. 2003
  27. ncbi request reprint Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Ill, USA
    Am Heart J 145:S60-1. 2003
  28. ncbi request reprint Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization
    Parag Jain
    Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S3-17. 2003
  29. ncbi request reprint Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry
    Victor L Serebruany
    Johns Hopkins University, Sinai Hospital, Baltimore, MD, USA
    Pathophysiol Haemost Thromb 32:8-15. 2002
    ..Taken together, opposite to our expectations, major clinical characteristics of heart failure did not correlate well with the platelet characteristics investigated in this study...
  30. ncbi request reprint Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA
    Am Heart J 143:1068-75. 2002
    ..We sought to determine whether platelet activity in patients with heart failure is related to an ischemic versus nonischemic etiologic condition, clinical disease severity, or adverse clinical outcomes...
  31. ncbi request reprint Beta-adrenergic blockers in chronic congestive heart failure
    Wendy A Gattis
    Am J Health Syst Pharm 59:467-9. 2002